NEW YORK, NY, May 1, 2026
SK Capital Partners, LP announced the successful completion of the sale of Noramco Group, including Noramco, Extractas Biosciences, and Purisys, to Siegfried Holding AG, a global Contract Development and Manufacturing Organization (CDMO). The transaction marks a significant M&A milestone in the pharmaceutical manufacturing sector, reinforcing consolidation trends as companies seek to scale capabilities and strengthen global supply chains.
Strategic Acquisition Expands CDMO Capabilities
The acquisition enables Siegfried to significantly expand its portfolio in active pharmaceutical ingredients (APIs) and controlled substances manufacturing, strengthening its position as a leading global CDMO partner. Noramco Group brings deep expertise in complex APIs, high-potency compounds, and regulatory-controlled substances, which are increasingly critical in modern drug development. By integrating these capabilities, Siegfried is expected to enhance end-to-end service offerings, from early-stage development through commercial manufacturing, improving its competitiveness in a rapidly evolving pharmaceutical outsourcing market. This move reflects a broader industry trend toward vertical integration and specialization in high-value manufacturing segments.
SK Capital Retains Halo Pharmaceuticals for Growth
As part of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals, a finished-dose CDMO with operations in the United States and Canada. Halo will continue operating independently, with existing leadership, including CEO Lee Karras and CFO Alan Majewski, remaining in place. The company is actively pursuing capacity expansion initiatives, including the planned launch of sterile injectable manufacturing at its New Jersey facility, expected in the second half of 2026. This strategic decision indicates SK Capital’s focus on scaling high-growth CDMO segments, particularly in sterile manufacturing and specialized dosage forms, where demand continues to rise due to biologics and complex therapies.
Advertisement
M&A Reflects Industry Consolidation and Growth Focus
This transaction highlights ongoing consolidation in the pharmaceutical services sector, driven by the need for integrated manufacturing solutions, regulatory expertise, and global scale. Financial advisory for the deal was led by Jefferies, with additional support from RBC Capital Markets and Rothschild & Co., while Kirkland & Ellis served as legal counsel. For SK Capital, the divestiture represents a successful value-creation cycle, having strengthened Noramco’s operational and strategic positioning during its ownership period. For Siegfried, the acquisition aligns with its long-term strategy to expand high-margin, specialized manufacturing capabilities and meet growing demand from pharmaceutical clients worldwide.
The deal underscores a clear industry direction: CDMOs are evolving into fully integrated partners, and companies lacking scale or specialization are being absorbed into larger platforms. As pharmaceutical pipelines become more complex, such strategic acquisitions are expected to accelerate innovation, improve supply chain resilience, and enhance manufacturing efficiency across the sector.
Source: SK Capital Partners press release
